NEW YORK, Sept. 01, 2017 -- The Klein Law Firm announces that a class action complaint has been filed on behalf of shareholders of Depomed, Inc. (NASDAQ:DEPO) who purchased shares between February 26, 2015 and August 7, 2017. The action, which was filed in the United States District Court for the Northern District of California, alleges that the Company violated federal securities laws.
In particular, the complaint alleges that throughout the Class Period, defendants made materially false and/or misleading statements and/or failed to disclose that (i) Depomed engaged in questionable practices in connection with the sales and marketing of the Company’s opioid products; (ii) the foregoing conduct, when it became known, would likely subject the Company to heightened legal and regulatory scrutiny; and (iii) as a result, Depomed’s public statements were materially false and misleading at all relevant times.
On August 7, 2017, post-market, Depomed disclosed that the Company “received a request for information from the ranking minority member of the United States Senate Committee on Homeland Security and Governmental Affairs related to the promotion of opioids” and that the Company had received “subpoenas related to opioid sales and marketing from the Office of the Attorney General of Maryland and the United States Department of Justice.”
Shareholders have until October 17, 2017 to petition the court for lead plaintiff status. Your ability to share in any recovery does not require that you serve as lead plaintiff. You may choose to be an absent class member.
If you suffered a loss during the class period and wish to obtain additional information, please contact Joseph Klein, Esq. by telephone at 212-616-4899 or visit http://www.kleinstocklaw.com/pslra-sb/depomed-inc?wire=3.
Joseph Klein, Esq. is an experienced attorney and has also practiced as a Certified Public Accountant. Mr. Klein represents investors and participates in securities litigations involving financial fraud throughout the nation. Attorney advertising. Prior results do not guarantee similar outcomes.
CONTACT: Joseph Klein, Esq. Empire State Building 350 Fifth Avenue 59th Floor New York, NY 10118 Telephone: (212) 616-4899 Fax: (347) 558-9665 www.kleinstocklaw.com


MATCH Act Targets ASML and Chinese Chipmakers in New U.S. Export Crackdown
Norma Group Posts Revenue Decline in 2025, Eyes Modest Recovery in 2026
Jefferies Upgrades Sodexo to Buy With €55 Target After Historic CEO Appointment
Fonterra Admits Anchor Butter "Grass-Fed" Label Misled Consumers After Greenpeace Lawsuit
Ukrainian Drones and the #MadeByHousewives Movement: Kyiv Fires Back at Rheinmetall CEO
Brazil Meat Exports Weather Iran War Disruptions With Rerouted Shipments
BlackRock CEO Larry Fink Earns $37.7 Million in 2025 Amid Record Growth
Cathay Pacific Holds Firm on Flight Capacity Amid Middle East Conflict and Rising Fuel Costs
Annie Altman Amends Sexual Abuse Lawsuit Against OpenAI CEO Sam Altman
Tesla Q1 2026 Deliveries Miss Estimates as AI Strategy Takes Center Stage
SoftwareONE Posts 22.5% Revenue Surge in 2025 on Crayon Acquisition
McDonald's and Restaurant Brands International Face Headwinds Amid Iran Conflict and Rising Costs
Nike Beats Q3 Estimates but China Weakness and Margin Pressure Weigh on Outlook
SpaceX Eyes Historic IPO at $1.75 Trillion Valuation
KPMG UK Cuts 440 Audit Jobs Amid Low Attrition and Cooling Professional Services Demand
Russell 1000 Companies Hit $2.2T Cash Record While Aggressively Reinvesting in Growth
Eli Lilly and Insilico Medicine Forge $2.75 Billion AI-Driven Drug Discovery Deal 



